ALS drug trial halted: no meaningful benefit seen

NCT ID NCT06441682

Ongoing Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 22, 2026 · Updated 21 times

Summary

This study tested a drug called ARGX-119 in 60 adults with ALS to see if it was safe and could slow the disease. The trial was stopped early because early results showed it was unlikely to help patients. The decision was not due to safety concerns, and follow-up visits are still happening.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Aarhus Universitets Hospital

Aarhus, 8200, Denmark
Akademiskt specialistcentrum Karolinska Institutet

Stockholm, 113 61, Sweden
Bispebjerg University Hospital

Copenhagen, 2400, Denmark
CHU Bretonneau

Tours, 37000, France
Hôpital La Pitié Salpêtrière

Paris, 75013, France
Kaye Edmonton Clinic

Edmonton, 11400, Canada
Montreal Neurological Institute and Hospital

Montreal, H3A 2B4, Canada
UMC Utrecht

Utrecht, 3584 CX, Netherlands
UZ Leuven

Leuven, 3000, Belgium

Conditions

Explore the condition pages connected to this study.

AMYOTROPHIC LATERAL SCLEROSIS